BioAlliance Pharma: First Meeting of the DSMB of the ReLive Trial and Continuation Without Modification of the Phase III Clinical Trial With Livatag® in Primary Liver Cancer

Published: Dec 06, 2012

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) held its first meeting on the ReLive Phase III trial and recommended continuing it without modification to evaluate the efficacy of Livatag® (doxorubicin Transdrug™) in primary liver cancer.

Back to news